US · JUNS
Jupiter Neurosciences, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Jupiter, FL 33477
- Website
- jupiterorphan.com
Price · as of 2024-12-31
$0.39
Market cap 18.25M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $0.00 | $15.41 | |||
| 2022 | $0.00 | $7.92 | |||
| 2023 | |||||
| 2024 | $0.67 |
AI valuation
Our deep-learning model estimates Jupiter Neurosciences, Inc.'s (JUNS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $0.39
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| JUNS | Jupiter Neurosciences, In… | $0.39 | 18.25M | — | — | — | — | -7.90 | 4.62 | — | -7.18 | — | 4.62 | 0.00% | — | — | 299.46% | 208.79% | -76.83% | 0.05 | -12.45 | 2.31 | 1.88 | 1.62 | -3943.00% | — | 71318.00% | -20.28% | -1.95 | 264.16% | 0.00% | 0.00% | 29.93% | -5.09 | -4.02 | — | -1.31 |
| ABVC | ABVC BioPharma, Inc. | $1.31 | 18.98M | +6,706% | +707,778% | — | — | -1.42 | 6.08 | 14.64 | -2.24 | — | 6.08 | 99.85% | -923.34% | -962.12% | -378.31% | -131.15% | -68.64% | 2.61 | -5.70 | 0.33 | 0.32 | -0.54 | -7667.00% | 23431.00% | -5701.00% | -24.25% | -0.28 | -51.48% | 0.00% | 0.00% | 0.10% | -2.07 | -5.38 | 19.10 | -14.83 |
| ALGS | Aligos Therapeutics, Inc. | $7.03 | 43.26M | -26% | -26% | — | +18,737% | -0.62 | -2.80 | 20.55 | -0.38 | -0.12 | -2.80 | 100.00% | -2259.92% | -3326.01% | -415.84% | 162.06% | -118.41% | -0.29 | — | 2.86 | 2.62 | 0.33 | 49489.00% | -7460.00% | 235.00% | -99.76% | -3.71 | 147.01% | 0.00% | 0.00% | 0.00% | -0.36 | -0.40 | 8.24 | -15.30 |
| FGEN | FibroGen, Inc. | $9.07 | 36.69M | +230% | -59% | — | +42% | -19.49 | -4.11 | 31.31 | -6.67 | — | -4.11 | 47.47% | -507.80% | -160.63% | 22.14% | 63.58% | -14.91% | -0.32 | -18.24 | 1.47 | 0.60 | -0.16 | -8356.00% | -3671.00% | -5646.00% | -14.91% | -1.04 | 58.55% | 0.24% | -4.70% | 3.92% | -6.32 | -6.87 | 32.07 | -12.76 |
| GNTA | Genenta Science S.p.A. | $0.99 | 18.96M | — | — | — | — | -6.66 | 4.75 | — | -4.80 | — | 4.78 | 0.00% | — | — | -54.13% | -1295.77% | -47.95% | 0.00 | — | 6.89 | 6.72 | 0.47 | -2344.00% | — | -4434.00% | -10.53% | -2.97 | -828.69% | 0.00% | 0.00% | 1.48% | -4.78 | -7.48 | — | 8.82 |
| GRCE | Grace Therapeutics, Inc. | $4.29 | 60.61M | — | — | — | — | -3.75 | 0.54 | — | -0.83 | — | 2.07 | 0.00% | — | — | -14.91% | -30.04% | -13.17% | 0.00 | — | 11.77 | 11.53 | 1.33 | -5434.00% | — | 2063.00% | -41.52% | -7.72 | -35.82% | 0.00% | 0.00% | 0.00% | -0.83 | -0.92 | — | -0.71 |
| KZR | Kezar Life Sciences, Inc. | $6.70 | 49.07M | +394% | — | — | — | -5.31 | 3.80 | — | -4.05 | — | 3.80 | 0.00% | — | — | -55.00% | -3029.25% | -45.77% | 0.14 | -56.88 | 6.76 | 6.53 | 0.32 | -1786.00% | -10000.00% | -1104.00% | -16.69% | -3.65 | -2482.15% | 0.00% | 0.00% | 2.03% | -3.63 | -4.43 | — | 4.31 |
| MRSN | Mersana Therapeutics, Inc… | $29.08 | 145.36M | +85% | +9,159% | — | — | -0.96 | -7.01 | 1.65 | 0.62 | — | -7.01 | 95.98% | -181.09% | -170.86% | -505.14% | 57.77% | -37.33% | -3.01 | -18.93 | 2.19 | 2.16 | 1.25 | -6180.00% | 988.00% | -5178.00% | -123.65% | -1.32 | 64.97% | 0.00% | 0.00% | 0.00% | 0.54 | 0.48 | -0.97 | -9.18 |
| SKYE | Skye Bioscience, Inc. | $0.74 | 23.88M | — | — | — | — | -3.61 | 1.41 | — | -1.11 | — | 1.41 | 0.00% | — | — | -80.48% | -4256.79% | -62.73% | 0.01 | -31.20 | 16.32 | 15.77 | 2.69 | -8641.00% | — | 9221.00% | -27.97% | -5.82 | -3784.31% | 0.00% | 0.00% | 74.32% | -0.93 | -1.04 | — | 9.69 |
| XFOR | X4 Pharmaceuticals, Inc. | $3.44 | 39.24M | — | +23% | — | — | -1.89 | 3.20 | 27.68 | -1.70 | — | -13.60 | 68.83% | -1423.58% | -1464.61% | -102.26% | 1092.96% | -25.50% | 3.53 | -4.15 | 3.41 | 3.16 | -0.81 | -6731.00% | — | 3589.00% | -185.42% | -3.98 | 3940.16% | 0.00% | 0.00% | 0.00% | -1.29 | -0.36 | 18.30 | -4.74 |
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.
- CEO
- Christer Rosen
- Employees
- 4
- Beta
- 2.59
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $0.39) − 1 = — (DCF, example).